Form 4: BioLargo Director Receives Equity Compensation

BioLargo, Inc. director Christina Bray was granted options to purchase 115,741 shares of common stock as compensation for board services.

Summary

• Christina Bray, a Director of BioLargo, Inc. (BLGO), was granted an option to purchase 115,741 shares of common stock.
• The option was issued on March 31, 2026, with an exercise price of $0.162 per share.
• This grant serves as payment for $18,750 in fees due to Ms. Bray for her services on the board of directors during the most recently completed quarterly period.
• The option is exercisable immediately on March 31, 2026, and expires on March 31, 2036.
• The number of shares in the option was calculated by dividing the $18,750 in fees by the $0.162 exercise price.
• Following this transaction, Ms. Bray beneficially owns 1,381,502 derivative securities (options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine compensation disclosure for a director, reflecting standard corporate governance practices rather than a significant operational or financial development.

Positives

• BioLargo, Inc. is utilizing its 2024 Equity Incentive Plan to compensate directors, which can help conserve cash resources.
• Compensating directors with equity aligns their financial interests with those of the company's shareholders.

Negatives

• The issuance of stock options introduces potential future dilution for existing shareholders if the options are exercised.

Risks

• Potential dilution of existing shareholder value if the 115,741 options granted are exercised in the future.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategy, beyond the terms of the granted option.

Industry Context

StockSavvy.ai notes that compensating directors with equity, such as stock options, is a common practice across various industries. This method helps companies conserve cash, especially smaller or growth-stage firms, and aligns the interests of board members with long-term shareholder value. This particular grant is a routine compensation event within the biotech/environmental technology sector.

Comparison to Industry Standards

• The use of equity compensation for directors is a standard practice, comparable to how many public companies, particularly those in the small-cap and growth sectors like BioLargo, incentivize their leadership.
• The specific value of the compensation ($18,750 for a quarterly period) and the number of options granted (115,741) are within typical ranges for non-executive directors at companies of similar market capitalization, though exact comparisons would require detailed peer group analysis.

Corporate Governance

Related Party Transactions

• The grant of stock options to Christina Bray, a director of BioLargo, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefit from aligned director incentives.
• Directors: Christina Bray receives compensation for her services, incentivizing her continued contribution to the board.

Key Dates

Keywords

BioLargo, BLGO, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Incentive Plan, Corporate Governance